{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"105"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"355"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"description":"The number of participants experiencing serious adverse events (SAEs).\n\nA serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event.","groups":[{"description":"Participants receive BMS-986213 (IV fixed-dose combination relatlimab/nivolumab at a 1:3 ratio) every 4 weeks (Q4W).\n\nFor adults, dosing is relatlimab 160 mg/nivolumab 480 mg. Adolescents ≥ 40 kg will receive adult dosing; for adolescents \\< 40 kg, dosing is relatlimab 2 mg/kg/nivolumab 6 mg/kg.","id":"OG000","title":"Arm A: Relatlimab + Nivolumab"},{"description":"Participants receive Nivolumab IV monotherapy every 4 weeks (Q4W).\n\nDosing for adults is 480 mg. Adolescents ≥ 40 kg will receive adult dosing; for adolescents \\< 40 kg, dosing is 6 mg/kg.","id":"OG001","title":"Arm B: Nivolumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days after last dose of study therapy (up to approximately 33 months)","title":"The Number of Participants Experiencing Serious Adverse Events (SAEs)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}